OrthoPediatrics | 8-K: OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2025 Financial Results
This 8-K filing announces that OrthoPediatrics Corp. has reported its financial results for both the fourth quarter and the full year of 2025. This indicates a formal disclosure of the company's financial performance. Investors and analysts would review this document for detailed financial data and future outlook.
Enterprise value to EBITDA forward of OrthoPediatrics Corp. – LSX:A2JAAV
This article provides financial information for OrthoPediatrics Corp. (LSX:A2JAAV) on TradingView, specifically focusing on its enterprise value to EBITDA forward. It indicates market details, including that the market is closed with no current trades.
Price to sales forward of OrthoPediatrics Corp. – NASDAQ:KIDS
This article provides the "Price to sales forward" metric for OrthoPediatrics Corp. (NASDAQ: KIDS) on TradingView. It indicates the stock market, company name, and general financial information availability. The content is brief and contains no specific numerical data or in-depth analysis.
Price to book forward of OrthoPediatrics Corp. – LSX:A2JAAV
The article provides financial information for OrthoPediatrics Corp. (LSX: A2JAAV), specifically focusing on its "Price to book forward" metric. It appears to be a stub or a data-focused page from TradingView, offering a quick overview of this financial ratio for the company.
OrthoPediatrics Corp. Actuals & Estimates (NASDAQ:KIDS)
This article provides an overview of OrthoPediatrics Corp. (NASDAQ:KIDS) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details financial data such as recent earnings, revenue, and EBITDA, along with information on future earnings report dates. The company's stock volatility, employee count, and dividend policy are also covered.
OrthoPediatrics Announces Distribution Agreement with OSSIO, Inc. to Provide Revolutionary Orthopedic Fixation Technology to U.S. Children’s Hospitals Nationwide
OrthoPediatrics Corp. has announced an exclusive distribution agreement with OSSIO, Inc. to bring bio-integrative, metal-free orthopedic fixation technology to U.S. children's hospitals. This technology uses OSSIO fiber implants that are gradually replaced by new bone, reducing the need for secondary hardware removal surgeries common with metal implants in pediatric patients. This partnership enhances OrthoPediatrics' product offerings and aims to address unmet pediatric orthopedic needs while strengthening the company's growth potential.
KIDS Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast and financial overview for OrthoPediatrics Corp. (KIDS), including analyst price targets, past performance, and upcoming earnings dates. It covers key financial metrics like EPS, revenue, market capitalization, net income, and EBITDA, addressing frequently asked questions about the stock.
OrthoPediatrics’ Shift to Sterile Packaging Streamlines Pediatric Implant Care
OrthoPediatrics has converted its IM nail implant portfolio from non-sterile to sterile packaging, redesigning over 1,300 SKUs. This initiative, highlighted at The PACK Out, aims to reduce OR burden, improve hospital workflow, and support scalable growth in pediatric orthopedics. The project successfully decreased packaging complexity from over ten carton sizes to just two by utilizing 3D-printed prototypes and adaptable packaging components.
Orthopediatrics Corp announces a distribution agreement with Ossio, Inc. to introduce revolutionary orthopedic fixation technology to children's hospitals across the United States
Orthopediatrics Corp has signed a distribution agreement with Ossio, Inc. to bring advanced orthopedic fixation technology to children's hospitals across the United States. This collaboration aims to improve surgical outcomes and recovery processes for young patients. The partnership is expected to provide healthcare institutions with more innovative and reliable medical product options in pediatric orthopedics.
OSSIO Inc.’s Distribution Deal With OrthoPediatrics Corp. Brings Bio-Integrative, Metal-Free OSSIOfiber® Implants to U.S. Children’s Hospitals Nationwide – Ortho Spine News
OSSIO Inc. has signed an exclusive distribution agreement with OrthoPediatrics Corp. to bring its bio-integrative, metal-free OSSIOfiber® implants to children's hospitals across the U.S. These implants are designed to be gradually replaced by the patient's own bone, eliminating the need for a second surgery to remove hardware, which is particularly beneficial for pediatric patients. This partnership aims to accelerate the adoption of this revolutionary orthopedic fixation technology, addressing bone fractures and skeletal deformities in children.
OrthoPediatrics lands metal-free implant deal
OrthoPediatrics Corp. has secured an exclusive distribution agreement with Ossio to introduce metal-free fixation technology to U.S. children's hospitals. The deal involves Ossiofiber implants, which are designed to treat fractures and deformities in pediatric patients and are gradually replaced by new bone, eliminating the need for hardware removal. This bio-integrative solution offers initial fixation strength comparable to metal and fully integrates into bone within 18-24 months.
OrthoPediatrics partners with OSSIO for bio-integrative implants
OrthoPediatrics Corp. has entered into an exclusive distribution agreement with OSSIO, Inc. to provide bio-integrative, metal-free fixation technology for pediatric fracture and deformity treatment in U.S. children’s hospitals. This partnership aims to reduce the need for second surgeries to remove metal implants, as OSSIO's implants are designed to be absorbed and replaced by bone. OrthoPediatrics, a company focused solely on pediatric orthopedics, reported strong financial results in Q1 2026, surpassing Wall Street expectations, and received a reiterated Buy rating from TD Cowen.
KIDS: Pediatric Orthopedic Execution And 2026 Guidance Will Drive Upside Potential
This article analyzes OrthoPediatrics (KIDS) through recent analyst commentary, highlighting both bullish and bearish perspectives. It discusses how updated assumptions on discount rates, profit margins, and future P/E expectations have led to recalibrated price targets for the stock. The article also covers recent company news, including new product launches and adjusted 2026 revenue guidance.
Orthopediatrics Corp announces a distribution agreement with Ossio, Inc. to introduce revolutionary orthopedic fixation technology to children's hospitals across the United States
Orthopediatrics Corp has partnered with Ossio, Inc. through a distribution agreement to bring advanced orthopedic fixation technology to children's hospitals throughout the U.S. This collaboration aims to significantly improve orthopedic treatment for young patients by providing innovative solutions that enhance surgical outcomes and the recovery process. The agreement marks a crucial step for both companies in advancing pediatric orthopedic technology and offering more reliable medical product options to healthcare institutions.
OrthoPediatrics adds metal-free implants for children’s hospitals
OrthoPediatrics (NASDAQ: KIDS) has signed an exclusive U.S. distribution agreement with OSSIO to bring OSSIOfiber bio-integrative, metal-free fixation implants to children's hospitals nationwide. These implants are designed to treat pediatric fractures and deformities, gradually integrating into bone within 18-24 months and reducing the need for secondary hardware removal surgeries. This partnership enhances OrthoPediatrics' trauma portfolio and aims to address unmet pediatric orthopedic needs while strengthening the company's long-term growth potential.
OrthoPediatrics Announces Distribution Agreement with
OrthoPediatrics Corp. has announced an exclusive distribution agreement with OSSIO, Inc. to provide U.S. children's hospitals with bio-integrative, metal-free fixation technology. This technology, using OSSIO fiber implants, is designed to reduce the need for secondary hardware removal surgeries in pediatric patients by integrating with the patient's bone during the healing process. This partnership enhances OrthoPediatrics' product offerings and aims to address unmet needs in pediatric orthopedics.
Tranche Update on OrthoPediatrics Corp.'s Equity Buyback Plan announced on August 5, 2024.
OrthoPediatrics Corp. has provided a tranche update on its equity buyback plan, originally announced on August 5, 2024. As of March 31, 2026, the company has not repurchased any shares under this specific buyback program. The update indicates that 0 shares have been repurchased for $0 million between January 1, 2026, and March 31, 2026.
OrthoPediatrics Corp (KIDS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for OrthoPediatrics Corp (KIDS) by business segments and regions, updated as of April 6. The company's primary revenue drivers are Trauma and Deformity, comprising 70.36% of revenue, followed by Scoliosis at 27.94%. Regionally, the U.S. accounts for the majority of revenue at 78.87%.
OrthoPediatrics Corp (KIDS) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of OrthoPediatrics Corp (KIDS) stock, focusing on its dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and has no historical stock split data available. The page also presents current stock performance metrics and market capitalization for KIDS.
OrthoPediatrics Corp (KIDS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of OrthoPediatrics Corp (KIDS), listing major shareholders such as Squadron Capital LLC and Brown Advisory, along with their respective proportions. It also provides a breakdown of institutional holdings over several quarters, showing the number of institutions and shares held. Additionally, the report includes information on related ETFs that hold KIDS stock.
OrthoPediatrics Corp (KIDS) Financial Health: Profitability & Balance Sheet Analysis
OrthoPediatrics Corp (KIDS) currently holds a robust financial score of 7.25, ranking 93rd out of 203 in the Healthcare Equipment & Supplies industry. The company reported a latest quarterly revenue of $59.36M, marking a 13.26% year-over-year increase, while its net profit saw a slight increase of 0.26% year-over-year. This analysis highlights the company's strong financial health and high operating efficiency, despite some specific financial data not yet being disclosed.
OrthoPediatrics Corp (KIDS) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for OrthoPediatrics Corp (KIDS), indicating its current valuation score is 9.11, ranking 43 out of 203 in its industry. The company's P/E ratio is noted as -11.01, with other key valuation metrics like P/B, P/S, and P/CF not yet disclosed by the company. The stock closed at $18.580 with a market cap of $475.94M.
TD Cowen reiterates OrthoPediatrics stock Buy rating at $23 target
TD Cowen has reiterated a Buy rating for OrthoPediatrics Corp. (NASDAQ:KIDS) with a $23 price target, citing four key themes from recent meetings with company leadership: a new product "Supercycle," managed growth for cash and profitability, a long revenue runway, and market opportunities. The firm believes OrthoPediatrics' growth and profitability inflection is currently underappreciated and undervalued. The company recently surpassed Q1 2026 earnings expectations, reporting an EPS of -$0.45 and revenue of $59.4 million.
TD Cowen reiterates OrthoPediatrics stock Buy rating at $23 target By Investing.com
TD Cowen reiterated a Buy rating on OrthoPediatrics Corp. (NASDAQ:KIDS) with a price target of $23.00, citing four key themes discovered during recent meetings with the company's CEO and CFO, including a new product "Supercycle" and underappreciated growth. The firm believes the company's growth and profitability inflection story is undervalued in the market, despite analysts not anticipating profitability this year. This reiteration follows OrthoPediatrics’ strong first-quarter 2026 earnings, which surpassed Wall Street expectations for both EPS and revenue.
Orthopediatrics (NASDAQ: KIDS) director awarded 11,436 shares in new stock grant
Orthopediatrics (NASDAQ: KIDS) director Samuel D. Riccitelli was granted 11,436 shares of common stock as equity compensation, increasing his direct ownership to 31,859 shares, which includes 17,959 restricted stock awards. This transaction, a routine stock grant, was reported on a Form 4 and indicates no cash cost per share, signaling compensation rather than a market purchase. The filing suggests a neutral impact and sentiment regarding the director's view of the stock's short-term valuation.
[Form 4] ORTHOPEDIATRICS CORP Insider Trading Activity
OrthoPediatrics Corp. director David R. Pelizzon reported receiving a stock award of 11,436 common shares on June 9, 2026, increasing his direct holdings to 44,384 shares, including 17,959 restricted stock awards. The filing also notes his indirect beneficial ownership of 6,901,764 shares through Squadron Capital LLC, although he disclaims beneficial ownership beyond his pecuniary interest. This transaction impacts his total share count and highlights the compensation structure for company insiders.
[Form 4] ORTHOPEDIATRICS CORP Insider Trading Activity
This article reports on a Form 4 insider trading activity for ORTHOPEDIATRICS CORP (KIDS) involving Harold Ruf. The filing indicates three transactions with a neutral impact and sentiment. Harold Ruf acquired 11,436 shares of common stock at $0.00, increasing his total direct holdings to 19,837 shares and indirect holdings in various trusts to 19,247 shares.
[Form 4] ORTHOPEDIATRICS CORP Insider Trading Activity
This article details an insider trading transaction for ORTHOPEDIATRICS CORP (KIDS) reported on SEC Form 4. Bryan W. Hughes, a Director, acquired 11,436 shares of common stock at a price of $0.00 on June 9, 2026, bringing his total direct holdings to 32,663 shares, which includes 17,959 restricted stock awards. The filing indicates a "Neutral" impact and sentiment.
OrthoPediatrics Corp stock (US68735M1027): pediatric implant specialist in focus after latest earnin
OrthoPediatrics Corp, a specialist in pediatric orthopedic implants, recently released its latest quarterly earnings report, highlighting continued procedure growth in pediatric trauma, deformity correction, and scoliosis. The company's business model focuses exclusively on orthopedic solutions for children and adolescents, a niche market with fewer direct competitors. Recent results show ongoing revenue growth for the Nasdaq-listed KIDS stock, emphasizing the importance of scale, margin management, and investment in product development.
(KIDS) Volatility Zones as Tactical Triggers
This article provides an AI-driven analysis for Orthopediatrics Corp. (NASDAQ: KIDS), indicating a near-term neutral sentiment but suggesting a pause in mid and long-term weakness. It highlights a significant short setup with an exceptional risk-reward ratio and outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
OrthoPediatrics Corp. Files 8-K Report Detailing Executive Compensation and Auditor Approval – June 2026
OrthoPediatrics Corp. (NASDAQ: KIDS) announced the results of its 2026 Annual Meeting of Stockholders, detailing key decisions on director elections, executive compensation, and an amendment to its 2024 Incentive Award Plan. Shareholders approved the compensation of named executive officers and ratified Deloitte & Touche LLP as the independent auditor. The expansion of the Incentive Award Plan allowing for 2,050,000 additional shares could lead to dilution but also aims to attract and retain talent.
Shareholders of OrthoPediatrics (NASDAQ: KIDS) approve plan share increase
OrthoPediatrics Corp. (NASDAQ: KIDS) shareholders approved several key proposals at their 2026 Annual Meeting. They re-elected four directors, endorsed executive compensation in an advisory vote, and significantly increased the shares authorized under the 2024 Incentive Award Plan by 2,050,000, bringing the total to 3,679,000 shares. Additionally, Deloitte & Touche LLP was ratified as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
OrthoPediatrics COO and CFO Fred Hite in Goldman Sachs fireside chat June 8
OrthoPediatrics (KIDS) announced that its COO and CFO, Fred Hite, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 2:40 pm ET. The session will be webcast live on the company’s investor relations website, with a replay also available. This event continues OrthoPediatrics' ongoing investor outreach, which has historically correlated with positive stock performance.
OrthoPediatrics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
OrthoPediatrics Corp. (Nasdaq: KIDS) announced that its Chief Operating Officer and Chief Financial Officer, Fred Hite, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026, at 2:40 pm ET in Miami Beach, FL. A webcast of the discussion will be available on the company's investor relations website. OrthoPediatrics specializes in pediatric orthopedics, offering nearly 90 systems for trauma and deformity, scoliosis, and sports medicine.
OrthoPediatrics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
OrthoPediatrics Corp. (Nasdaq: KIDS) announced that Fred Hite, COO and CFO, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 2:40 pm ET in Miami Beach, FL. A webcast and replay of the discussion will be available on the OrthoPediatrics investor relations website. The company focuses exclusively on advancing pediatric orthopedics with a comprehensive product offering.
OrthoPediatrics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
OrthoPediatrics Corp. (Nasdaq: KIDS) announced that its COO and CFO, Fred Hite, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026, at 2:40 pm ET. An audio webcast and replay will be available on the company's investor relations website. OrthoPediatrics specializes in pediatric orthopedics, offering a comprehensive product line across trauma and deformity, scoliosis, and sports medicine.
OrthoPediatrics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
OrthoPediatrics Corp. (Nasdaq: KIDS) announced its Chief Operating Officer and Chief Financial Officer, Fred Hite, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference. The event is scheduled for June 8, 2026, at 2:40 pm ET in Miami Beach, FL. An audio webcast and replay will be available on the company's investor relations website.
OrthoPediatrics Corp stock (US68735M1027): pediatric specialist reports Q1 2025 growth and raised ou
OrthoPediatrics Corp reported strong Q1 2025 revenue growth and increased its full-year sales outlook, driven by continued demand for its pediatric orthopedic implants and trauma systems. The company specializes exclusively in medical devices for children and adolescents, differentiating itself from larger orthopedic manufacturers. This niche focus makes it an appealing investment for those interested in specialized medtech and pediatric care, though investors should be aware of the inherent volatility in specialized markets.
Orthopediatrics Corp Raises Outlook Amid EBITDA Turnaround
Orthopediatrics Corp (KIDS) reported a positive Q1 earnings call, highlighting accelerating growth, improved margins, and a return to positive adjusted EBITDA. The company saw record patient reach, double-digit revenue growth both domestically and internationally, and raised its full-year 2026 revenue guidance. Despite ongoing net losses, management expressed confidence in their strategy, driven by new product launches, specialty bracing expansion, and EU MDR approvals.
OrthoPediatrics Corp stock (US68735M1027): pediatric orthopedics specialist updates investors after latest earnings
OrthoPediatrics Corp, a specialist in pediatric orthopedics, recently released its latest quarterly figures, updating investors on its strategy. The company focuses exclusively on orthopedic solutions for children and adolescents, developing implants and instruments tailored to young patients' anatomy and growth patterns. Its core business revolves around proprietary systems for trauma, deformity correction, and spinal indications, commercialized through specialist sales teams and distribution partners working with pediatric hospitals.
OrthoPediatrics (Nasdaq:KIDS) - Análisis de acciones
This article provides a detailed analysis of OrthoPediatrics (Nasdaq:KIDS), a medical device company specializing in orthopedic products for children. It covers the company's financial performance, future growth prospects, past results, financial health, and recent news, including various analyst ratings and product announcements. The analysis highlights that the stock is currently not profitable and has experienced significant insider selling, yet analysts see potential in its long-range revenue outlook and new product launches.
Number of shareholders of OrthoPediatrics Corp. – NASDAQ:KIDS
This article provides financial information for OrthoPediatrics Corp. (NASDAQ: KIDS), specifically focusing on the number of shareholders. It appears to be a financial data snippet from TradingView, including market data and copyright information.
OrthoPediatrics (NASDAQ: KIDS) counsel gifts 2,479 Common Stock shares
OrthoPediatrics Corp.'s General Counsel and Secretary, Daniel J. Gerritzen, gifted 2,479 shares of Common Stock without receiving payment. Following this transaction, Gerritzen directly holds 147,054 shares, which include 121,054 restricted stock awards. This filing is classified as a neutral event, solely representing a bona fide gift.
OrthoPediatrics stock (US68735M1027): Pediatric orthopedic device maker trades near resistance
OrthoPediatrics Corp (KIDS) is trading at $17.79 on Nasdaq, with analysts giving it a "Moderate Buy" rating and a price target of $24.44, suggesting a 37.6% upside. The company specializes in pediatric orthopedic medical devices and has a market capitalization of $456.7 million. This niche focus and strong analyst sentiment make it an interesting play for investors in the medical device sector, despite modest year-to-date performance.
Is the Selloff in OrthoPediatrics Corp. (KIDS) Creating a Buying Opportunity?
Minot Light Capital Partners, in its Q1 2026 investor letter, highlighted OrthoPediatrics Corp. (NASDAQ: KIDS) as a top-10 holding despite its recent stock decline. The firm views current market volatility as creating attractive opportunities in out-of-favor sectors and has been increasing its stake in OrthoPediatrics. While acknowledging the company's potential, Minot Light Capital also suggests that certain AI stocks might offer higher returns in a shorter timeframe.
Canaccord Genuity initiates coverage of OrthoPediatrics (KIDS) with buy recommendation
Canaccord Genuity has initiated coverage of OrthoPediatrics (KIDS) with a buy recommendation. This positive analyst outlook indicates a belief in the company's future stock performance.
OrthoPediatrics Corp. Announces Preliminary Unaudited Financial Highlights for the Fourth Quarter & Full Year 2023
OrthoPediatrics Corp. announced preliminary unaudited net revenue for Q4 and full year 2023, along with its 2024 financial guidance. The company expects Q4 2023 revenue of $37.6 million (21% growth) and full-year 2023 revenue of $148.7 million (22% growth). For 2024, OrthoPediatrics projects revenue between $197 million and $200 million, including contributions from its recent acquisition of Boston O&P, which is expected to be accretive to adjusted EBITDA in 2024.
KIDS SEC Filings - Orthopedia 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to OrthoPediatrics (KIDS) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside insider trading documents. It details OrthoPediatrics' financial condition, operations, and governance, with AI-powered summaries to highlight key information from regulatory disclosures. Investors can track material events, financial statements, and corporate actions.
OrthoPediatrics (KIDS) Q1 Losses Challenge Bullish Margin Narratives Despite 11.1% Revenue Growth
OrthoPediatrics (KIDS) reported Q1 2026 revenue of US$59.4 million and a US$0.45 basic EPS loss, marking continued unprofitability despite 11.1% annual revenue growth. Trailing 12-month net losses reached US$39.7 million, challenging bullish narratives about margin improvement. The stock trades at a P/S discount compared to peers, which analysts attribute to persistent losses and recent insider selling rather than weaker top-line performance.
OrthoPediatrics (NASDAQ: KIDS) posts 13% Q1 revenue rise but remains unprofitable
OrthoPediatrics Corp. (NASDAQ: KIDS) reported a 13% increase in Q1 2026 net revenue, reaching $59.4 million, driven by strong performance in trauma and deformity, scoliosis, and specialty bracing across both U.S. and international markets. Despite this revenue growth and maintaining a strong gross margin of 73%, the company recorded a net loss of $10.7 million, similar to the prior year, illustrating continued unprofitability. OrthoPediatrics also increased its liquidity with a new $20 million delayed draw term loan facility and saw an increase in goodwill to $115.2 million due to recent clinic acquisitions.
